DC Vaccination to Enhance Adoptive T Cell Transfer

细胞免疫系统在调节癌症患者的抗肿瘤反应方面具有很大的潜力。黑色素瘤 对研究免疫疗法特别有吸引力，因为T细胞识别的几种黑色素瘤特异性抗原 在过去的十年里已经被发现。在最近的临床试验中，转移性黑色素瘤患者接受体外- 扩增的肿瘤反应性T细胞显示出令人鼓舞的临床反应，特别是当与 过继细胞移植(ACT)前的淋巴滤除方案。然而，在许多患者中，输注的T细胞并没有 细胞移植后可长时间增殖或存活，未见肿瘤消退。这一观察结果表明 增加T细胞在体内的持久性将改善ACT后的临床反应。在我们的初步研究中，我们 已经评估了肿瘤抗原致敏的树突状细胞(DC)作为一种免疫策略来改善过继T细胞 回应。使用小鼠模型，我们发现DC免疫导致过继免疫显著增殖。 转移的T细胞，介导对大型皮下肿瘤的增强免疫反应。虽然这一角色 树突状细胞在调节内源性幼稚和静息T细胞的强烈刺激方面的作用得到了很好的证明，它们能够 提高过继转移的活化T细胞的有效性构成了DC的一个新用途。我们假设 这一原则在患者中也适用，抗原特异的过继转移的T细胞与 肿瘤抗原肽致敏的树突状细胞可增强转移的T细胞在体内的持久性 激活和功能，并改善运输到肿瘤部位，最终导致改善临床反应。 在临床试验的背景下，我们建议在本申请中调查特定DC的作用 免疫在过继转移的抗原特异性T细胞的持久性、功能和表型形成中的作用 细胞。这项建议的目标是获得关于DC对ACT的影响的知识，并利用这一点 改善转移性癌症患者过继免疫治疗的信息。 这项建议的具体目的是：(1)确定多肽冲击的DC免疫是否可以改变 过继转移的外周抗原特异性T细胞的持久性、细胞表面表型和功能 (2)评估多肽冲击的DC免疫是否增强过继转移抗原的能力。 特异性T细胞在肿瘤部位的渗透和功能：以及(3)确定患者的临床反应和评估 反应是否与T细胞的持续性、表型、功能和肿瘤侵袭程度相关。这些 研究可能揭示树突状细胞与过继转移的T细胞之间相互作用的原理 这可能允许为患者设计改进的免疫治疗策略。 我

The cellular immune system holds much potential for mediating antitumor responses in cancer patients. Melanoma is particularly appealing to study immunotherapy, since several melanoma-specific antigens recognized by T cells have been identified over the past decade. In recent clinical trials, metastatic melanoma patients receiving ex vivo- expanded tumor-reactive T cells have demonstrated encouraging clinical responses, particularly when combined with a lymphodepletion regimen prior to adoptive cell transfer (ACT). However, in many patients, the infused T cells did not proliferate or survive long after cell transfer and no tumor regression was observed. This observation has suggested that increasing T cell persistence in vivo will improve clinical responses following ACT.In our preliminary studies, we have assessed tumor antigen-pulsed dendritic cells (DCs)as an immunization strategy to improve adoptive T cell responses. Using a murine model, we found that DC immunization resulted in significant proliferation of adoptively transferred T cells which mediated enhanced immune responses against large subcutaneous tumors. While the role of DCs in mediating strong stimulation of endogenous naive and resting T cells is well documented, their ability to increase the efficacy of adoptively transferred activated T cells constitutes a novel use of DCs.We hypothesize that this principle will hold true in patients, and that the combination of antigen-specific, adoptively transferred T cells with tumor antigen peptide-pulsed DCs will result in enhanced persistence of the transferred T cells in vivo, increased activation and function, and improved trafficking to tumor sites, ultimately leading to improved clinical responses. Within the context of a clinical trial, we are proposing in this application to investigate the role that specific DC immunization plays in shaping the persistence, function, and phenotype of adoptively transferred antigen-specific T cells. The goals of this proposal are to acquire knowledge about the influence of DCs on ACT and to use this information to improve adoptive immunotherapy of patients with metastatic cancer. The specific aims of this proposal are:(1) Determine if peptide-pulsed DC immunization can alter the persistence, cell surface phenotype, and function of adoptively transferred, antigen-specific T cells in the peripheral blood; (2) Assess whether peptide-pulsed DC immunization enhances the ability of adoptively transferred, antigen- specific T cells to infiltrate and function at the tumor site: and (3) Determine patient clinical responses and assess whether response correlates with T-cell persistence, phenotype, function, and degree of tumor infiltration. These studies may uncover principles regarding the interaction between dendritic cells and adoptively transferred T cells in vivo which may allow the design of improved immunotherapy strategies for patients. i